文献速递艾滋病与性传播感染病毒性肝炎

含替诺福韦抗逆转录病毒治疗时代HIV与乙型肝炎病毒共感染者中丁型肝炎病毒感染的发生率与结局

Incidence and Outcome of Hepatitis D Virus Infection in People With HIV and Hepatitis B Virus Coinfection in the Era of Tenofovir-Containing Antiretroviral Therapy.
PubMed 文献 · Clin Infect Dis · 2026-01-01

该研究纳入2011至2022年534例HBV共感染的HIV感染者,随访至2023年12月。含替诺福韦ART时代HDV年发病率为12.54/1000人年,HDV感染与肝相关死亡相关(调整HR 9.696)。

要点

  • 基线HDV血清阳性率为6.7%(36/534),随访期间HDV血清阳转率为10.0%(50/498)。
  • HDV血清阳转者中88.0%(44/50)为男男性行为者。
  • HDV感染与肝相关死亡相关,调整HR为9.696(95%CI 1.284-73.222,P=.028)。

核心结论

  • 在含替诺福韦ART时代,HBV共感染的HIV感染者仍存在HDV重叠感染风险,且HDV感染与肝相关死亡相关。

研究设计与样本

  • 研究纳入2011年至2022年HBV共感染的HIV感染者,随访至2023年12月,使用连续存档血样进行抗-HDV抗体筛查。
  • 共纳入534例HBV共感染的HIV感染者,随访3987.78人年。

主要发现

  • 基线时36例(6.7%)抗-HDV血清阳性。
  • 随访期间498例抗-HDV阴性者中50例(10.0%)HDV血清阳转,总发病率为12.54/1000人年。
  • HDV血清阳转者中88.0%(44/50)为男男性行为者。
  • 中位随访10.2年(含替诺福韦ART覆盖84.7%的随访期),全因死亡率为4.7%(25/534)。
  • HDV感染者较HDV未感染者肝相关死亡率更高(3.5% vs 0.4%,P=.032)、肝硬化发生率更高(11.3% vs 3.6%,P=.008)、肝炎 flare 发生率更高(28.2% vs 14.2%,P=.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tenofovir-containing antiretroviral therapy (ART) improves survival in hepatitis B virus (HBV)-coinfected people with HIV (PWH). We investigated the incidence of hepatitis D virus (HDV) infection and its clinical impact in HBV-coinfected PWH in the era of tenofovir-containing ART. METHODS: Between 2011 and 2022, HBV-coinfected PWH were included and followed until December 2023. Anti-HDV antibody screening was performed using sequentially archived blood samples. Timing of incident HDV infection was estimated as the midpoint between the last timepoint of anti-HDV-negative samples and the first timepoint of anti-HDV-positive samples. Differences in survival and liver-related outcomes between HDV-infected and -uninfected PWH were analyzed. RESULTS: 534 HBV-coinfected PWH were included; 36 (6.7%) tested HDV-seropositive at baseline. During 3987.78 person-years of follow-up (PYFU), 50 (10.0%) of 498 anti-HDV-negative PWH seroconverted for HDV, with an overall incidence rate of 12.54 per 1000 PYFU; 88.0% (44/50) of HDV seroconverters were men who have sex with men. After a median follow-up of 10.2 years (84.7% of the follow-up period covered by tenofovir-containing ART), all-cause mortality was 4.7% (25/534). PWH with HDV had significantly higher rates of liver-related mortality (3.5% vs 0.4%, P = .032), cirrhosis (11.3% vs 3.6%, P = .008), and hepatitis flare (28.2% vs 14.2%, P = .001) than HDV-uninfected PWH. In multivariate Cox analysis, HDV infection was associated with liver-related mortality (adjusted HR, 9.696; 95% CI, 1.284-73.222, P = .028). Risk of hepatocellular carcinoma was similar for HDV-infected and HDV-uninfected PWH. CONCLUSIONS: HBV-coinfected PWH remain at risk of HDV superinfection and HDV infection is associated with liver-related death in the era of tenofovir-containing ART.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Huang YS, Sun HY, Ho SY, et al. Incidence and Outcome of Hepatitis D Virus Infection in People With HIV and Hepatitis B Virus Coinfection in the Era of Tenofovir-Containing Antiretroviral Therapy. Clin Infect Dis. 2026. PMID: 39745917. doi:10.1093/cid/ciae655

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。